Kinetical analysis of tumor cell death-inducing mechanism by polymorphonuclear leukocyte-derived calprotectin: involvement of protein synthesis and generation of reactive oxygen species in target cells.
We have previously shown that calprotectin, the most abundant cytosolic protein existing in polymorphonuclear leukocytes (PMNs), induces apoptotic cell death in various tumor cells, suggesting that calprotectin is an effector molecule against tumor cells in PMNs. To explore the cell death-inducing mechanism of the factor, we examined the involvement of target protein synthesis and generation of reactive oxygen species (ROS) in the reaction. Calprotectin induced cell death in MM46 mouse mammary carcinoma cells after a 14-16 hr lag time. When the factor was removed from the medium up to about 12 hr after culturing, the effect was diminished. The induction of cell death by calprotectin was markedly inhibited by the presence of the RNA synthesis inhibitor actinomycin D or the protein synthesis inhibitor cycloheximide. However, the addition of these inhibitors after 12 hr of culturing was unable to inhibit the reaction. Up to 12 hr of culturing, the net protein synthesis of MM46 cells was augmented by the presence of calprotectin, but thereafter was impaired. The induction of cell death was also inhibited by the antioxidative reagents N-acetyl-L-cysteine (NAC) or propyl gallate. The addition of NAC even 15 hr later significantly attenuated the calprotectin effect. Flow cytometry analysis showed that calprotectin began to increase the ROS content in MM46 cells after 8-12 hr of culturing, and that the increase was abrogated by the antioxidants. Thus, protein synthesis and ROS generation may be essential elements in the early or later phases of the cell death-inducing reaction of calprotectin, respectively.
Mikami
M
M
Faculty of Pharmaceutical Sciences, Teikyo University, Kanagawa, Japan.
Yamazaki
M
M
Yui
S
S
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D017209:Apoptosis; D002277:Carcinoma / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D006801:Humans; D039841:Leukocyte L1 Antigen Complex; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism*; D051379:Mice; D008809:Mice, Inbred C3H; D009363:Neoplasm Proteins / Q000096:biosynthesis; D019006:Neural Cell Adhesion Molecules / Q000494:pharmacology*; D009504:Neutrophils / Q000276:immunology*; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D012334:RNA, Neoplasm / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D000975:Antioxidants; D004273:DNA, Neoplasm; D039841:Leukocyte L1 Antigen Complex; D009363:Neoplasm Proteins; D019006:Neural Cell Adhesion Molecules; D019384:Nucleic Acid Synthesis Inhibitors; D011500:Protein Synthesis Inhibitors; D012334:RNA, Neoplasm; D017382:Reactive Oxygen Species